Triple-negative breast cancers (TNBCs) are distinguished by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and constitutes up to 20% of all breast cancers cases. This evidence concerns the gene ESR1 and breast cancer.